NON-MYELOBLATIVE HAPLOIDENTICAL HSCT WITH NK CELL INFUSIONS IN HIGH RISK MYELOID

高风险骨髓中 NK 细胞输注的非成髓性单倍体 HSCT

• 批准号: 7375910
• 负责人: DANIEL J WEISDORF
• 金额: $ 0.48万
• 依托单位: UNIVERSITY OF MINNESOTA
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7375910
• 关键词: NON; MYELOBLATIVE; HAPLOIDENTICAL; HSCT; NK

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study is being done to evaluate the effects of an infusion of natural killer (NK) celss given to patients receiving a reduced intensity pre-transplant regimen and stem cell trnsplant from a haploidentical related donor. Our hypothesis is that the addition of NK cells to this standard regimen will reduce the incidence of GVHD without compromising engraftment or leading to excess day +100 mortality. Additionally, the NK cell infusion may limit the risks of cancer relapse after transplant. We are also testing the safety of the NK cell infusion.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子弹和调查员（PI）可能已经从其他NIH来源获得了主要资金，因此可以在其他清晰的条目中代表。列出的机构适用于该中心，这不一定是调查员的机构。这项研究是为了评估从单倍型相关供体中降低强度移植前治疗方案和干细胞TRNSplant的患者的自然杀伤（NK）摄入的影响。我们的假设是，将NK细胞添加到该标准方案中将降低GVHD的发生率，而不会损害植入或导致过度的一天+100死亡。另外，NK细胞输注可能会限制移植后癌症复发的风险。我们还正在测试NK细胞输注的安全性。